tremelimumab   Click here for help

GtoPdb Ligand ID: 8462

Synonyms: CP-675 | CP-675,206 | CP-675206 | Imjudo® | ticilimumab | tremelimumab-actl
Approved drug Immunopharmacology Ligand
tremelimumab is an approved drug (FDA (2022), EMA (2023))
Compound class: Antibody
Comment: Tremelimumab is a fully human investigational monoclonal antibody targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA4, CD152). Tremelimumab was designed as an antineoplastic agent. A BLAST sequence alignment matches tremelimumab to patent US 6682736, and identifies antibody clone 11.2.1 [2].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
Classification Click here for help
Compound class Antibody
Ligand families/groups Immune checkpoint modulators
Approved drug? Yes (FDA (2022), EMA (2023))
International Nonproprietary Names Click here for help
INN number INN
8716 tremelimumab
Synonyms Click here for help
CP-675 | CP-675,206 | CP-675206 | Imjudo® | ticilimumab | tremelimumab-actl
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 248
Other databases
GtoPdb PubChem SID 252166672
Search PubMed clinical trials tremelimumab
Search PubMed titles tremelimumab
Search PubMed titles/abstracts tremelimumab
Wikipedia Tremelimumab